How to appeal a Cigna lupus & rheumatology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for lupus & rheumatology

Cited policy: Cigna coverage policy: Saphnelo (Anifrolumab-fnia) for Moderate-to-Severe SLE

Adult ≥18 yr with moderate-to-severe SLE meeting EULAR/ACR 2019 criteria, on standard therapy (HCQ + GC ± MMF/AZA/MTX) with active disease (SLEDAI-2K ≥6 or BILAG A in any organ). 300 mg IV q4wk. Type-I IFN gene signature testing not required. Reauth 6 mo with BICLA response or SLEDAI-2K reduction ≥4 with GC taper.

How Cigna denies lupus & rheumatology — and how to counter it

Where Cigna pushes back: 1) Must try Benlysta first; 2) TULIP-1 missed primary endpoint, efficacy questioned; 3) Lupus nephritis not on label.

Counter-arguments that hold up: TULIP-2 NEJM 2020 met BICLA primary endpoint 47.8% vs 31.5% placebo (p=0.001); pooled TULIP-1+TULIP-2 reanalysis using BICLA showed consistent benefit. FDA approved Aug 2021 based on totality of evidence including MUSE Phase 2. EULAR 2023 places anifrolumab equal-weight with belimumab for non-renal SLE refractory to standard ISD — NO mandated sequence. Saphnelo blocks type-I-IFN receptor (IFNAR1) — distinct mechanism from BLyS-targeting belimumab; failure of one does not predict the other. LN exclusion is appropriate; this request is for non-renal moderate-to-severe SLE with active cutaneous + musculoskeletal + serologic disease.

What Cigna typically denies for lupus & rheumatology

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For lupus & rheumatology, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the lupus & rheumatology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Benlysta
• Saphnelo
• Lupkynis
• Hydroxychloroquine
• Mycophenolate (MMF)
• Cyclophosphamide IV

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.